CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan Injection; Stocks Rise PALO ALTO, Calif., April 15 -- CV Therapeutics, Inc. announced today ...
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Dr. Reddy's is offering ...
Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...
Just a week after gaining regulatory approval for Lexiscan (regadenoson), an injection that increases arterial blood flow during heart tests, CV Therapeutics sold off a 50 percent interest in its ...
Shares of CV Therapeutics Inc. rose 17.6 percent Wednesday on news that the firm received $175 million in cash from New York-based investment firm TPG-Axon Capital in exchange for rights to 50 percent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback